CAN
PBYI icon

Cetera Advisor Networks’s Puma Biotechnology PBYI Stock Holding History

Cetera Advisor Networks’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,500
Closed -$26K – 2488
2020
Q2 		$26K Buy
+2,500
New +$25.9K ﹤0.01% 2256

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Cetera Advisor Networks's PBYI Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Puma Biotechnology (PBYI) in Q3 2020, closing a stake of 2,500 shares — an estimated $26K sold.

Cetera Advisor Networks first reported a position in PBYI in Q2 2020 and held it in 1 quarter. The position peaked at $26K in Q2 2020. 128 funds tracked by Wall St. Rank hold PBYI as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Puma Biotechnology position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 2,500 Puma Biotechnology shares in Q3 2020, an estimated $26K.
  • Cetera Advisor Networks first reported a position in Puma Biotechnology in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Puma Biotechnology position peaked at $26K in Q2 2020.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.